Literature DB >> 7534290

CD14: physical properties and identification of an exposed site that is protected by lipopolysaccharide.

M D McGinley1, L O Narhi, M J Kelley, E Davy, J Robinson, M F Rohde, S D Wright, H S Lichenstein.   

Abstract

Soluble CD14 (sCD14) is a 55-kDa serum protein that binds lipopolysaccharide (LPS) and mediates LPS-dependent responses in a variety of cells. Using recombinant sCD14 expressed in Chinese hamster ovary (CHO) cells, we examined the structural characteristics of sCD14 and sCD14.LPS complexes. The circular dichroism and fluorescence spectra of the sCD14 indicate that it contains substantial beta-sheet (40%) and a well-defined tertiary structure with the tryptophan residues located in environments with different degrees of hydrophobicity and solvent exposure. The spectra of the sCD14.LPS complex are identical within experimental error to the uncomplexed sCD14. Changes in surface accessibility upon LPS binding were examined using limited proteolysis with endoproteinase Asp-N. This analysis revealed that aspartic acid residues at amino acids 57, 59, and 65 are susceptible to cleavage by Asp-N, while the same residues are protected from proteolytic cleavage in the sCD14.LPS complex. These results suggest that a region including amino acids 57 to 64 is involved in LPS binding by sCD14.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534290     DOI: 10.1074/jbc.270.10.5213

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation.

Authors:  D Filipp; K Alizadeh-Khiavi; C Richardson; A Palma; N Paredes; O Takeuchi; S Akira; M Julius
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

2.  Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis.

Authors:  Mesut Ogrendik; Siranus Kokino; Ferda Ozdemir; Philip S Bird; Stephen Hamlet
Journal:  MedGenMed       Date:  2005-06-16

Review 3.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS.

Authors:  B W Jarvis; H Lichenstein; N Qureshi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation.

Authors:  K Le-Barillec; M Si-Tahar; V Balloy; M Chignard
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14.

Authors:  M D Cunningham; C Seachord; K Ratcliffe; B Bainbridge; A Aruffo; R P Darveau
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

7.  Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages.

Authors:  P Y Perera; N Qureshi; S N Vogel
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 8.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Solution NMR studies provide structural basis for endotoxin pattern recognition by the innate immune receptor CD14.

Authors:  Seth Albright; Bin Chen; Kristen Holbrook; Nitin U Jain
Journal:  Biochem Biophys Res Commun       Date:  2008-01-28       Impact factor: 3.575

10.  Pseudomonas aeruginosa slime glycolipoprotein is a potent stimulant of tumor necrosis factor alpha gene expression and activation of transcription activators nuclear factor kappa B and activator protein 1 in human monocytes.

Authors:  George Lagoumintzis; Myrto Christofidou; George Dimitracopoulos; Fotini Paliogianni
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.